𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines

✍ Scribed by Matthias J. Schnell; Gene S. Tan; Bernhard Dietzschold

Book ID
111739327
Publisher
Springer US
Year
2005
Tongue
English
Weight
187 KB
Volume
11
Category
Article
ISSN
1355-0284

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo